TLR7 and hepatitis B virus infection: A CpG-based adjuvant is used in an FDA-approved hepatitis B vaccine (Heplisav-B), and the ssRNA component in the influenza A WIV vaccine is critical for its intrinsic adjuvant activity via TLR7 activation (47).